Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1570-1646
  • E-ISSN: 1875-6247

Abstract

Introduction

Proteins present in body fluids harbor the potential to act as markers for both diagnosing diseases and exploring their underlying mechanisms. As urine can be easily obtained non-invasively, analyzing its proteins is an ideal approach to identifying biomarkers for bladder cancer. This study aimed to identify proteins in urine that could serve as biomarkers for bladder cancer.

Methods

Urine samples were collected from patients with primary transitional cell carcinoma of the bladder and their age and sex-matched healthy individuals. The protein pellet underwent resolubilization and trypsin digestion to facilitate analysis using reverse phase nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry.

Results

In samples obtained from 16 patients and 8 controls, 3192 peptides were identified, corresponding to 934 unique proteins, of which 60 were identified with higher confidence levels. Among them, Transferrin and Prostaglandin D2 Synthase (PTGDS) were found as potential markers of bladder cancer. In particular, the absence of PTGDS has a specificity of 100% and a sensitivity of 81%.

Conclusion

This study, which used proteomic approaches, identified PTGDS in urine as a potential biomarker of bladder cancer.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cp/10.2174/0115701646315079240919085008
2024-10-03
2025-10-31

  • From This Site

    /content/journals/cp/10.2174/0115701646315079240919085008
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. VlahouA. SchellhammerP.F. MendrinosS. PatelK. KondylisF.I. GongL. NasimS. WrightG.L.Jr Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.Am. J. Pathol.200115841491150210.1016/S0002‑9440(10)64100‑411290567
     [Google Scholar]
  2. ShokeirA.A. Squamous cell carcinoma of the bladder: Pathology, diagnosis and treatment.BJU Int.200493221622010.1111/j.1464‑410X.2004.04588.x14690486
     [Google Scholar]
  3. FleshnerN.E. HerrH.W. StewartA.K. MurphyG.P. MettlinC. MenckH.R. The National cancer data base report on bladder carcinoma.Cancer1996787150515138839558
     [Google Scholar]
  4. ZhangJ. ZhengS. GaoY. RotoloJ.A. XiaoZ. LiC. ChengS. A partial allelotyping of urothelial carcinoma of bladder in the Chinese.Carcinogenesis200325334334710.1093/carcin/bgh01514604888
     [Google Scholar]
  5. UnderwoodW.III DunnR.L. WilliamsC. LeeC.T. Gender and geographic influence on the racial disparity in bladder cancer mortality in the US.J. Am. Coll. Surg.2006202228429010.1016/j.jamcollsurg.2005.09.00916427554
     [Google Scholar]
  6. TêtuB. TiguertR. HarelF. FradetY. ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma.Mod. Pathol.2005181838910.1038/modpathol.380026215389253
     [Google Scholar]
  7. American Joint committee on CancerManual for staging of cancer. BeahrsOA. HensonDE. HutterRVP. MyersMH.
    [Google Scholar]
  8. MostifiF.K. Histological typing of urinary bladder tumours.1973Available from: https://iris.who.int/handle/10665/41533
  9. BradfordM.M. A rapid and sensitive method for the quantities of protein.Anal. Biochem.19767224825410.1016/0003‑2697(76)90527‑3942051
     [Google Scholar]
  10. WashburnM.P. WoltersD.A. YatesJ.R. Large- scale analysis of the yeast proteome by multidimentional technology.Nat. Biotechnol.20011924224710.1038/8568611231557
     [Google Scholar]
  11. TyanY.C. GuoH.R. LiuC.Y. LiaoP.C. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry.Anal. Chim. Acta2006579215817610.1016/j.aca.2006.07.03317723740
     [Google Scholar]
  12. OhJ. PyoJ.H. JoE.H. HwangS.I. KangS.C. JungJ.H. ParkE.K. KimS.Y. ChoiJ.Y. LimJ. Establishment of a near-standard two-dimensional human urine proteomic map.Proteomics20044113485349710.1002/pmic.20040101815529407
     [Google Scholar]
  13. PieperR. GatlinC.L. McGrathA.M. MakuskyA.J. MondalM. SeonarainM. FieldE. SchatzC.R. EstockM.A. AhmedN. AndersonN.G. SteinerS. Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots.Proteomics2004441159117410.1002/pmic.20030066115048996
     [Google Scholar]
  14. PangJ.X. GinanniN. DongreA.R. HeftaS.A. OpiteckG.J. Biomarker discovery in urine by proteomics.J. Proteome Res.20021216116910.1021/pr015518w12643536
     [Google Scholar]
  15. ThongboonkerdV. McleishK.R. ArthurJ.M. KleinJ.B. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation.Kidney Int.20026241461146910.1111/j.1523‑1755.2002.kid565.x12234320
     [Google Scholar]
  16. SeymourG.J. WalshM.D. LavinM.F. StruttonG. GardinerR.A. Transferrin receptor expression by human bladder transitional cell carcinomas.Urol. Res.198715634134410.1007/BF002656633324443
     [Google Scholar]
  17. SchmetterB.S. HabichtK.K. LammD.L. MoralesA. BanderN.H. GrossmanH.B. HannaM.G.Jr SilbermanS.R. ButmanB.T. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer.J. Urol.1997158380180510.1016/S0022‑5347(01)64321‑09258086
     [Google Scholar]
  18. SteinJ.P. GrossfeldG.D. GinsbergD.A. EsrigD. FreemanJ.A. FigueroaA.J. SkinnerD.G. CoteR.J. Prognostic markers in bladder cancer: A contemporary review of the literature.J. Urol.199816064565910.1097/00005392‑199809010‑000039720515
     [Google Scholar]
  19. KonetyB.R. NguyenT.S.T. BrenesG. SholderA. LewisN. BastackyS. PotterD.M. GetzenbergR.H. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer.J. Urol.200016463463910.1016/S0022‑5347(05)67269‑210953114
     [Google Scholar]
  20. ChakrabortyA. DasariS. LongW. MohanC. Urine protein biomarkers for the detection, surveillance, and treatment response prediction of bladder cancer.Am. J. Cancer Res.2019961104111731285945
     [Google Scholar]
  21. GrossmanH.B. New methods for detection of bladder cancer.Semin. Urol. Oncol.199816117229508078
     [Google Scholar]
  22. IanariA. SternbergC.N. RossettiA. Van RijnA. DeiddaA. GiannarelliD. PansadoroV. Results of bard bta test in monitoring patients with a history of transitional cell cancer of the bladder.Urology199749578678910.1016/S0090‑4295(97)00081‑29145993
     [Google Scholar]
  23. PirtskalaishviliG. KonetyB.R. GetzenbergR.H. Update on urine-based markers for bladder cancer.Postgrad. Med.19991066859410.3810/pgm.1999.11.774
     [Google Scholar]
  24. SarosdyM.F. deVere WhiteR.W. SolowayM.S. SheinfeldJ. HudsonM.A. SchellhammerP.F. JarowenkoM.V. AdamsG. BlumensteinB.A. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer.J. Urol.1995154237938410.1016/S0022‑5347(01)67054‑X7609102
     [Google Scholar]
  25. SharmaS. ZippeC.D. PandrangiL. NelsonD. AgarwalA. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.J. Urol.19991621535710.1097/00005392‑199907000‑0001410379739
     [Google Scholar]
  26. VanarsaK. EnanS. PatelP. StrachanB. Sam TitusA.S.C.L. DennisA. LotanY. MohanC. Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens.Oncotarget202112878379010.18632/oncotarget.2794133889301
     [Google Scholar]
  27. HurleyL. SirokyMB. EdelstteinRA. KreneRJ. Neoplasms of the genitourinary tract.Manual of urology: Diagnosis and therapyLippincott Williams & Wilkins1999
     [Google Scholar]
  28. SpahrC.S. DavisM.T. McGinleyM.D. RobinsonJ.H. BuresE.J. BeierleJ. MortJ. CourchesneP.L. ChenK. WahlR.C. YuW. LuethyR. PattersonS.D. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry I.Profiling an unfractionated tryptic digest.Proteomics2001119310711680902
     [Google Scholar]
  29. HeineG. RaidaM. ForssmannW.G. Mapping of peptides and protein fragments in human urine using liquid chromatography–mass spectrometry.J. Chromatogr. A1997776111712410.1016/S0021‑9673(97)00440‑89286085
     [Google Scholar]
  30. JohanssonB. Urinary protein patterns in patients with uroepithelial tumours. Effect of surgery and radiotherapy.Scand. J. Urol. Nephrol.19759322122510.3109/003655975091342161209177
     [Google Scholar]
  31. HemmingsenL. RasmussenF. SkaarupP. WolfH. Urinary protein profiles in patients with urothelial bladder tumours.Br. J. Urol.198153432432910.1111/j.1464‑410X.1981.tb03189.x7260547
     [Google Scholar]
  32. JohanssonB. KistnerS. Proteinuria in patients with uroepithelial tumours with special regard to tumour size, clinical staging and grade of malignancy.Scand. J. Urol. Nephrol.197591454910.3109/003655975091399131215844
     [Google Scholar]
  33. HayashiO. NoguchiS. OyasuR. Transferrin as a growth factor for rat bladder carcinoma cells in culture.Cancer Res.19874717456045643621154
     [Google Scholar]
  34. GuoM. SunH. McArdleH.J. GamblingL. SadlerP.J. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride.Biochemistry20003933100231003310.1021/bi000798z10955990
     [Google Scholar]
  35. HuebersH.A. FinchC.A. The physiology of and receptors.Physiol. Rev.19876752052510.1152/physrev.1987.67.2.5203550839
     [Google Scholar]
  36. WhitneyJ.F. ClarkJ.M. GriffinT.W. GautamS. LeslieK.O. Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates.Cancer199576120258630872
     [Google Scholar]
  37. VandewalleB. GranierA.M. PeyratJ.P. BonneterreJ. LefebvreJ. Transferrin receptors in cultured breast cancer cells.J. Cancer Res. Clin. Oncol.19851101717610.1007/BF004025052991295
     [Google Scholar]
  38. IkutaK. FujimotoY. SuzukiY. TanakaK. SaitoH. OhhiraM. SasakiK. KohgoY. Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells.Biochim. Biophys. Acta Mol. Cell Res.200014962-322123110.1016/S0167‑4889(00)00016‑110771090
     [Google Scholar]
  39. ShibataT. KondoM. OsawaT. ShibataN. KobayashiM. UchidaK. 15-Deoxy-5-12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory process.J. Biol. Chem.2002277104591046610.1074/jbc.M11031420011786541
     [Google Scholar]
  40. ClayC.E. NamenA.M. AtsumiG. WillinghamM.C. HighK.P. KuteT.E. TrimboliA.J. FontehA.N. DawsonP.A. ChiltonF.H. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells.Carcinogenesis199920101905191110.1093/carcin/20.10.190510506103
     [Google Scholar]
  41. CallejasN.A. CastrilloA. BoscáL. Martín-SanzP. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators.J. Pharmacol. Exp. Ther.199928831235124110027864
     [Google Scholar]
  42. KikuchiY. MiyauchiM. OomoriK. KitaT. KizawaI. KatoK. Inhibition of human ovarian cancer cell growth in vitro and in nude mice by prostaglandin D2.Cancer Res.1986467336433663458525
     [Google Scholar]
  43. NithipatikomK. IsbellM.A. LindholmP.F. Kajdacsy-BallaA. KaulS. CampellW.B. Requirement of cyclooxygenese-2 expression and prostaglandin for human prostate cancer cell invasion.Clin. Exp. Metastasis200219759360110.1023/A:102091591437612498388
     [Google Scholar]
  44. ChinettiG. GriglioS. AntonucciM. TorraI.P. DeleriveP. MajdZ. FruchartJ.C. ChapmanJ. NajibJ. StaelsB. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.J. Biol. Chem.199827340255732558010.1074/jbc.273.40.255739748221
     [Google Scholar]
  45. FriedrichM.G. HellsternA. HautmannS.H. GraefenM. ConradS. HulandE. HulandH. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: A comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.J. Urol.2002168247047410.1016/S0022‑5347(05)64660‑512131290
     [Google Scholar]
  46. DiamandisE.P. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer.Clin. Chem.200450579379510.1373/clinchem.2004.03217715105344
     [Google Scholar]
  47. PattonS.E. HallM.C. OzenH. Bladder cancer.Curr. Opin. Oncol.200214326527210.1097/00001622‑200205000‑0000311981270
     [Google Scholar]
  48. EllisW.J. BlumensteinB.A. IshakL.M. EnfieldD.L. Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumors.Urology199750688288710.1016/S0090‑4295(97)00508‑69426718
     [Google Scholar]
  49. KauschI. BöhleA. Bladder Cancer.Eur. Urol.200139549850610.1159/00005249511464029
     [Google Scholar]
/content/journals/cp/10.2174/0115701646315079240919085008
Loading
Identifying Prostaglandin D2 Synthase in Urine: A Potential Biomarker for Bladder Cancer
Curr. Proteomics 21, 380 (2024); https://doi.org/10.2174/0115701646315079240919085008
/content/journals/cp/10.2174/0115701646315079240919085008
/content/journals/cp/10.2174/0115701646315079240919085008
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): biomarker; bladder cancer; mass spectrometry; Proteome; PTGDS; urine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test